These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31957953)

  • 1. Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy.
    Komaki H; Maegaki Y; Matsumura T; Shiraishi K; Awano H; Nakamura A; Kinoshita S; Ogata K; Ishigaki K; Saitoh S; Funato M; Kuru S; Nakayama T; Iwata Y; Yajima H; Takeda S
    Ann Clin Transl Neurol; 2020 Feb; 7(2):181-190. PubMed ID: 31957953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hematopoietic prostaglandin D synthase inhibitors for the treatment of duchenne muscular dystrophy].
    Kamauchi S; Urade Y
    Brain Nerve; 2011 Nov; 63(11):1261-9. PubMed ID: 22068479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a Guinea pig model of experimental allergic rhinitis.
    Aoyagi H; Kajiwara D; Tsunekuni K; Tanaka K; Miyoshi K; Hirasawa N
    Eur J Pharmacol; 2020 May; 875():173030. PubMed ID: 32084417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial.
    Reddy C; Patil AN; Suthar R; Sankhyan N; Sirari T; Kumar A; Bhattacharjee S; Saxena S; Saini AG; Sahu JK
    Eur J Paediatr Neurol; 2022 May; 38():77-84. PubMed ID: 35500465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.
    Voit T; Topaloglu H; Straub V; Muntoni F; Deconinck N; Campion G; De Kimpe SJ; Eagle M; Guglieri M; Hood S; Liefaard L; Lourbakos A; Morgan A; Nakielny J; Quarcoo N; Ricotti V; Rolfe K; Servais L; Wardell C; Wilson R; Wright P; Kraus JE
    Lancet Neurol; 2014 Oct; 13(10):987-96. PubMed ID: 25209738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of TAS-205 in patients with Duchenne muscular dystrophy.
    Takeshita E; Komaki H; Shimizu-Motohashi Y; Ishiyama A; Sasaki M; Takeda S
    Ann Clin Transl Neurol; 2018 Nov; 5(11):1338-1349. PubMed ID: 30480028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
    Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
    Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic Prostaglandin D Synthase Is Increased in Mast Cells and Pericytes in Autopsy Myocardial Specimens from Patients with Duchenne Muscular Dystrophy.
    Hamamura K; Yoshida Y; Oyama K; Li J; Kawano S; Inoue K; Toyooka K; Yamadera M; Matsunaga N; Matsumura T; Aritake K
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of prostaglandin D synthase suppresses muscular necrosis.
    Mohri I; Aritake K; Taniguchi H; Sato Y; Kamauchi S; Nagata N; Maruyama T; Taniike M; Urade Y
    Am J Pathol; 2009 May; 174(5):1735-44. PubMed ID: 19359520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
    Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Hafner P; Bonati U; Klein A; Rubino D; Gocheva V; Schmidt S; Schroeder J; Bernert G; Laugel V; Steinlin M; Capone A; Gloor M; Bieri O; Hemkens LG; Speich B; Zumbrunn T; Gueven N; Fischer D
    JAMA Netw Open; 2019 Oct; 2(10):e1914171. PubMed ID: 31664444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence JM; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz S
    Muscle Nerve; 2013 Sep; 48(3):343-56. PubMed ID: 23681930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
    Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
    Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.
    Finkel RS; McDonald CM; Lee Sweeney H; Finanger E; Neil Knierbein E; Wagner KR; Mathews KD; Marks W; Statland J; Nance J; McMillan HJ; McCullagh G; Tian C; Ryan MM; O'Rourke D; Müller-Felber W; Tulinius M; Burnette WB; Nguyen CT; Vijayakumar K; Johannsen J; Phan HC; Eagle M; MacDougall J; Mancini M; Donovan JM;
    J Neuromuscul Dis; 2021; 8(5):769-784. PubMed ID: 34120912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.